OKYO Pharma Limited- PDMR Dealing

LONDON and BOSTON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 200,000 ordinary shares of no par value in the market at prices between 5p and 5.5p per share.

The acquisitions increase Mr Cerrone's beneficial interests in the capital of

the Company from 52.64% to 52.66%.

1.	Details of PDMR / person closely associated
a)	Name	Gabriele Cerrone
2.	Reason for the notification
a)	Position / status	Chairman
b)	Initial notification /amendment	Initial notification
3.	Details of the issuer
a)	Name	OKYO Pharma Limited
b)	LEI	213800VVN5CB56Y15A05
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type  of transaction; (iii) each date; and (iv) each place where transactions have  been conducted
a)	Description of the financial instrument	Ordinary Shares of no par value
b)	Identification code of the Financial Instrument	ISIN for OKYO Pharma Limited: GG00BD3FV870
c)	Nature of the transaction	Market Purchase
d)	Price(s) and volume(s)	5p - 100,000 5.5p – 100,000
f)	Date of the transaction	26 January 2022
g)	Place of the transaction	XLON

Enquiries:

OKYO Pharma Limited	Gary S. Jacob, Chief Executive Officer Gabriele Cerrone, Non-Executive Chairman	+44 (0)20 7495 2379
Optiva Securities Limited (Broker)	Robert Emmet	+44 (0)20 3981 4173